Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE)

Q: What does CUSIP 03836J201 represent in this 13F holders report?

CUSIP 03836J201 is the security identifier for APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share in Q2 2023?

17 institutional investors reported APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share for Q2 2023. Use the holders table for investor-level position and value details.

CUSIP: 03836J201

Q2 2023 13F Holders as of 30 Jun 2023

Type / Class: Equity / Common stock, par value $0.001 per share
Shares outstanding: 9,144,889
Total 13F shares: 881,553
Share change: +33,316
Total reported value: $2,776,892
Price per share: $3.15
Number of holders: 17
Value change: +$105,033
Number of buys: 9
Number of sells: 2

Quarterly Holders Quick Answers

What is CUSIP 03836J201?
CUSIP 03836J201 identifies APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2023
Previous quarter: Q1 2023

Recent filing periods for CUSIP 03836J201:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of APRE - Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
AIGH Capital Management LLC	13F	Company	3.8%	345,000	$1,532,649	—	31 Mar 2023	13F
Sio Capital Management, LLC	13F	Company	3.1%	280,000	$1,243,200	—	31 Mar 2023	13F
Christian S. Schade	3/4/5	Director	— mixed-class rows	312,846 mixed-class rows	$976,345	—	28 Jul 2022	3/4/5
Scott M. Coiante	3/4/5	SVP, Chief Financial Officer	— mixed-class rows	234,265 mixed-class rows	$533,970	—	28 Jul 2022	3/4/5
Walleye Capital LLC	13F	Company	1%	93,263	$415,020	—	31 Mar 2023	13F
Worth Venture Partners, LLC	13F	Company	0.93%	84,869	$377,667	—	31 Mar 2023	13F
Eyal C. Attar	3/4/5	SVP, Chief Medical Officer, Director	— class O/S missing	57,392	$211,254	—	03 Jun 2022	3/4/5
Gregory Alan Korbel	3/4/5	SVP, Chief Operating Officer	— mixed-class rows	81,462 mixed-class rows	$168,445	—	28 Jul 2022	3/4/5
Lars B. Abrahmsen	3/4/5	SVP, Chief Scientific Officer	— mixed-class rows	143,700 mixed-class rows	$160,855	—	10 Mar 2022	3/4/5
VANGUARD GROUP INC	13F	Company	0.17%	15,501	$68,826	—	31 Mar 2023	13F
MORGAN STANLEY	13F	Company	0.16%	14,551	$64,606	—	31 Mar 2023	13F
BlackRock Finance, Inc.	13F	Company	0.1%	9,243	$41,039	—	31 Mar 2023	13F
Fouad Namouni	3/4/5	Director	— mixed-class rows	27,360 mixed-class rows	$16,969	—	30 Jun 2021	3/4/5
Michael Aaron Kelly	3/4/5	Director	— mixed-class rows	27,360 mixed-class rows	$16,969	—	30 Jun 2021	3/4/5
GROUP ONE TRADING LLC	13F	Company	0.02%	2,160	$9,612	—	31 Mar 2023	13F
Tower Research Capital LLC (TRC)	13F	Company	0.02%	1,477	$7,000	—	31 Mar 2023	13F
PNC FINANCIAL SERVICES GROUP, INC.	13F	Company	0.01%	1,000	$4,440	—	31 Mar 2023	13F
UBS Group AG	13F	Company	0.01%	674	$2,992	—	31 Mar 2023	13F
WELLS FARGO & COMPANY/MN	13F	Company	0%	264	$1,172	—	31 Mar 2023	13F
OSAIC HOLDINGS, INC.	13F	Company	0%	200	$888	—	31 Mar 2023	13F
Princeton Global Asset Management LLC	13F	Company	0%	100	$444	—	31 Mar 2023	13F
Kistler-Tiffany Companies, LLC	13F	Company	0%	25	$111	—	31 Mar 2023	13F
BANK OF AMERICA CORP /DE/	13F	Company	0%	10	$44	—	31 Mar 2023	13F
Quent Capital, LLC	13F	Company	0%	3	$13	—	31 Mar 2023	13F

Institutional Holders of Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) as of Q2 2023

As of 30 Jun 2023, Aprea Therapeutics, Inc. - Common stock, par value $0.001 per share (APRE) was held by 17 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 881,553 shares. The largest 10 holders included AIGH Capital Management LLC, Sio Capital Management, LLC, Walleye Capital LLC, Worth Venture Partners, LLC, GEODE CAPITAL MANAGEMENT, LLC, VANGUARD GROUP INC, MORGAN STANLEY, BlackRock Inc., Tower Research Capital LLC (TRC), and GROUP ONE TRADING, L.P.. This page lists 17 institutional shareholders reporting positions in this security for the Q2 2023 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2023 vs Q1 2023 Across Filers

Q1 2023 holders

Q2 2023 holders

Holder diff

Investor	Q1 2023 Shares	Q2 2023 Shares	Share Diff	Share Chg %	Q1 2023 Value $	Q2 2023 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.